Keyphrases
Israel
100%
Myelodysplastic Syndrome
100%
Decitabine
100%
Partial Response
30%
Hematologic Improvement
30%
Hypomethylating Agents
20%
Overall Response Rate
20%
Response Rate
20%
Complete Response
20%
Transfusion Requirements
20%
Tumor Suppressor Gene
20%
Total Response
20%
Leukemic Transformation
20%
Israeli
10%
Israeli Society
10%
Low Response
10%
Clinical Trials
10%
Median Overall Survival
10%
Intravenous Administration
10%
Malignancy
10%
Number of Patients
10%
Clinical Practice
10%
Tumor Inhibition
10%
Other-report
10%
Epigenetics
10%
Event-free Survival
10%
Neoplasms
10%
Treatment Line
10%
Blood Transfusion
10%
Novel Treatments
10%
Bone Marrow Suppression
10%
Transformation Rate
10%
Supportive Care
10%
Single Patient
10%
Vocal Cord Paralysis
10%
Hypomethylation
10%
5-aza-2′-deoxycytidine
10%
DNA Methyltransferase 1 (DNMT1)
10%
Hematology
10%
Response Criteria
10%
Helsinki
10%
Dacogen
10%
Advanced Degree
10%
Hypermethylation
10%
Cytosine Analogs
10%
Transfusion-free
10%
Response Enhancement
10%
Medicine and Dentistry
Myelodysplastic Syndrome
100%
Decitabine
100%
Tumor Suppressor Gene
20%
Disease
10%
Neoplasm
10%
Clinical Trial
10%
Overall Survival
10%
Malignant Neoplasm
10%
Cancer
10%
Event Free Survival
10%
Blood Transfusion
10%
Tumor Progression
10%
Bone Marrow Suppression
10%
Growth Inhibition
10%
Vocal Cord Paresis
10%
Supportive Care
10%
Hematology
10%
Cytosine
10%
DNA Methyltransferase
10%
Epigenomics
10%
Hypomethylating Agent
10%
Pharmacology, Toxicology and Pharmaceutical Science
Myelodysplastic Syndrome
100%
Decitabine
100%
Tumor Suppressor Protein
20%
Neoplasm
10%
Disease
10%
Malignant Neoplasm
10%
Clinical Trial
10%
Overall Survival
10%
Event Free Survival
10%
Tumor Growth
10%
Bone Marrow Suppression
10%
DNA Methyltransferase
10%
Cytosine
10%
Vocal Cord Paralysis
10%